World Library  
Flag as Inappropriate
Email this Article

Muscarine

Article Id: WHEBN0000242835
Reproduction Date:

Title: Muscarine  
Author: World Heritage Encyclopedia
Language: English
Subject: Acetylcholine, Muscarinic agonist, List of deadly fungi, Mushroom poisoning, Amanita muscaria
Collection: Alkaloids, Muscarinic Agonists, Mycotoxins, Quaternary Ammonium Compounds
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Muscarine

Muscarine
Chemical structure of muscarine
Names
IUPAC name
2,5-Anhydro-1,4,6-trideoxy-6-(trimethylammonio)-D-ribo-hexitol
Other names
L-(+)-muscarine, muscarin, (2S,4R,5S)-(4-hydroxy-5-methyl-tetrahydrofuran-2-ylmethyl)-trimethyl-ammonium
Identifiers
 Y
ChEMBL  Y
ChemSpider  Y
Jmol-3D images Image
PubChem
Properties
C9H20NO2+
Molar mass 174.26 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 Y  (: Y/N?)
Amanita muscaria

Muscarine, L-(+)-muscarine, or muscarin is a natural product found in certain mushrooms, particularly in Inocybe and Clitocybe species, such as the deadly C. dealbata. Mushrooms in the genera Entoloma and Mycena have also been found to contain levels of muscarine which can be dangerous if ingested. Muscarine has been found in harmless trace amounts in Boletus, Hygrocybe, Lactarius and Russula. Muscarine is only a trace compound in the fly agaric Amanita muscaria; the pharmacologically more relevant compound from this mushroom is muscimol. A. muscaria fruitbodies contain a variable dose of muscarine, usually around 0.0003% fresh weight. This is very low and toxicity symptoms occur very rarely. Inocybe and Clitocybe contain muscarine concentrations up to 1.6%.[1]

Muscarine is a nonselective agonist of the muscarinic acetylcholine receptor.

Contents

  • History 1
  • Structure and reactivity 2
    • Efficient synthesis of (+)-muscarine 2.1
    • Other Syntheses 2.2
  • Mechanism of action 3
  • Metabolism 4
  • Drug 5
  • Efficacy 6
  • Toxicology 7
  • Antidote 8
  • References 9
  • External links 10

History

Muscarine was first isolated from Amanita muscaria by German chemists Oswald Schmiedeberg and Richard Koppe, who reported their findings in 1869.[2] It was the first parasympathomimetic substance ever studied and causes profound activation of the peripheral parasympathetic nervous system that may end in convulsions and death. Being a quaternary ammonium salt, muscarine is less completely absorbed from the gastrointestinal tract than tertiary amines, but it does cross the blood-brain barrier.[3] Muscarinic agonists activate muscarinic receptors while nicotinic agonists activate nicotine receptors. Both are direct-acting cholinomimetics; they produce their effects by binding to and activating cholinergic receptors. Final proof of the structure was given by Franz Jellinek and colleagues in 1957 with the help of X-ray diffraction analysis;[4] Jellinek further described the three-dimensional structure of the molecule using muscarine chloride.[5] These new findings set into motion research not only on the pharmacology of muscarine, but also on that of muscarine-like substances that are structurally related to acetylcholine.

Structure and reactivity

‘Muscarine mimics the function of the natural neurotransmitter acetylcholine in the muscarinic part of the cholinergic nervous system", despite the less flexible structure due to the five-membered ring in the molecular skeleton.[6]

There are two mirror forms of muscarine, named: 2S-muscarine and 2R-muscarine.

Efficient synthesis of (+)-muscarine

The next is a very efficient way of synthesis of (+)-muscarine according to the scientists Chan and Li in the Canadian journal of Chemistry in 1992.[7] S-(−)-Ethyl lactate (2)(figure 3) is converted into the 2,6-dichlorobenzyl ether (3). Diisobutylaluminium hydride (DIBAL) reduction of the 2,6-dichlorobenzyl ether gives the aldehyde (4). Treatment of the crude aldehyde with allyl bromide and zinc powder in water with NH4Cl as catalyst resulted in an anti:syn mixture of 5a and 5b. Treatment of 5a with iodine in CH3CN at 0°C gives the cyclized product 6a. Finally treatment of 6a with excess trimethylamine in ethanol gave (+)-muscarine (2S,4R,5S). A similar reaction sequence with 5b gave (+)-epimuscarine (7).[7]

Figure 3. The scheme of synthesis of (+)-muscarine.

Other Syntheses

It can be synthesized in various ways from completely different substances,[8][9][10][11][12][13][14][15][16][17] particularly from 2,5-dimethyl-3-carboxymethyl flurane.

Mechanism of action

Muscarine mimics the action of the neurotransmitter acetylcholine by binding muscarinic acetylcholine receptors. These receptors were named after muscarine. There are 5 different types of muscarinic receptors; M1 - M5, and most tissues express a mixture of subtypes. The M2 and M3 subtypes mediate muscarinic responses at peripheral autonomic tissues. M1 and M4 subtypes are more abundant in brain and autonomic ganglia. M1, M3 and M5 interact with Gq proteins to stimulate phosphoinositide hydrolysis and the release of intracellular calcium. M2 and M4 receptors interact with Gi proteins to inhibit adenylyl cyclase, which results in a decrease of intracellular concentration of cyclic adenosine monophosphate (cAMP). Most agonists for muscarine receptors are not selective for subtypes.[18]

Metabolism

A paucity of research exists on the metabolism of muscarine in the human body, suggesting this compound is not metabolized by humans. Though there has been extensive research in the field of acetylcholine metabolism by acetylcholinesterase, muscarine is not metabolized by this enzyme, partly explaining the compound's potential toxicity. Muscarine is readily soluble in water. The most likely way for muscarine to leave the blood is via renal clearance; it will eventually leave the body in urine.[19]

Drug

Muscarinic agonists are used as drugs in treating glaucoma, postoperative ileus, congenital megacolon, urinary retention and xerostomia. Muscarine is contraindicated in patients with diseases that make them susceptible to parasympathetic stimulation, patients who have asthma or COPD or patients who have peptic ulcer disease. Also patients with an obstruction in the gastrointestinal or urinary tract are not prescribed muscarine because it will aggravate the obstruction, causing pressure to build up that may lead to perforation.

Efficacy

As muscarine works on the muscarinic acetylcholine receptor the best comparison can be made with acetylcholine, which normally works on this receptor. Pure muscarine compared to pure acetylcholine is stated in most cases to be more potent, its actions always slower but longer lasting than acetylcholine. A possible explanation for this long lasting behavior might be that muscarine does not get hydrolyzed by acetylcholinesterase in the synaptic cleft.[20]

Toxicology

Muscarine poisoning is characterized by miosis, blurred vision, increased salivation, excessive sweating, lacrimation, bronchial secretions, bronchoconstriction, bradycardia, abdominal cramping, increased gastic acid secretion, diarrhea and polyuria. If muscarine reaches the brain it can cause tremor, convulsions and hypothermia. Cardiac ventricles contain muscarinic receptors that mediate a decrease in the force of contractions leading to a lower blood pressure. If muscarine is administered intravenously, muscarine can trigger acute circulatory failure with cardiac arrest.[1] The symptoms of intoxication with mushrooms rich in muscarine, especially Inocybe, are very typical: The symptoms start early, after one-quarter to two hours, with headache, nausea, vomiting, and constriction of the pharynx. Then salivation, lacrimation, and diffuse perspiration set in, combined with miosis, disturbed accommodation, and reduced vision. Gastric and small bowel colic leads to diarrhea, and there is a painful urge for urination. Bronchoconstriction leads to asthmatic attacks and severe dyspnea, and bradycardia combined with marked hypotension and vasodilation results in circulatory shock. Death after 8 to 9 hours has been reported in about 5% of the cases, but can be avoided completely by prompt diagnosis and treatment with atropine.[21]

Antidote

The specific antidote is atropine. Atropine is also an alkaloid and inhibits acetylcholine and thus muscarine by binding to muscarinic receptors. Other muscarinic antagonists are scopolamine and pirenzepine. Muscarinic antagonists dilate the pupil and relax the ciliary muscle, are used in treatment of inflammatory uveitis and is associated with glaucoma. They are also used to treat urinary incontinence and diseases characterized by bowel hypermotility such as irritable bowel syndrome. Muscarinic antagonists are often called parasympatholytics because they have the same effect as agents that block postganglionic parasympatic nerves.

References

  1. ^ a b Lurie, Y; Wasser, SP; Taha, M; Shehade, H; Nijim, J; Hoffmann, Y; Basis, F; Vardi, M; Lavon, O; Suaed, S; Bisharat, B; Bentur, Y (July 2009). "Mushroom poisoning from species of genus Inocybe (fiber head mushroom): a case series with exact species identification". Clinical toxicology (Philadelphia, Pa.) 47 (6): 562–5.  
  2. ^ Schmiedeberg, O.; Koppe, R. (1869). L.), seine Darstellung, chemischen Eigenschaften, physiologischen Wirkungen, toxicologische Bedeutung und sein Verhältniss zur Pilzvergiftung im allgemeinenAgaricus muscarius Das Muscarin, das giftige Alkaloid des Fliegenpilzes (. Leipzig: Verlag von F.C.W. Vogel. 
  3. ^ Pappano Achilles J, "Chapter 7. Cholinoceptor-Activating & Cholinesterase-Inhibiting Drugs" (Chapter). Katzung BG: Basic & Clinical Pharmacology, 11e
  4. ^ Kögl, F.; Salemink, C.A.; Schouten, H.; Jellinek, F. (1957). "Über Muscarin. III". Recueil des Travaux Chimiques des Pays-Bas (in German) 76 (2): 109–127.  
  5. ^ Jellinek, F. (1957). "The structure of muscarine". Acta Crystallographica 10: 277–280.  
  6. ^ Frydenvang, K.; Jensen, B. (15 May 1993). "Structures of muscarine picrate and muscarine tetraphenylborate". Acta Crystallographica Section C Crystal Structure Communications 49 (5): 985–990.  
  7. ^ a b Chan, T. H.; Li, C. J. (November 1992). "A concise synthesis of (+)-muscarine". Canadian Journal of Chemistry 70 (11): 2726–2729.  
  8. ^ Kögl, F.; Salemink, C. A.; Schouten, H.; Jellinek, F. (2010). "Über Muscarin. III". Recueil des Travaux Chimiques des Pays-Bas 76 (2): 109.  
  9. ^ Kögl, F.; Cox, H. C.; Salemink, C. A. (1957). "Über Muscarin". Experientia 13 (4): 137.  
  10. ^ Corrodi, H.; Hardegger, E.; Kögl, F.; Zeller, P. (1957). "Synthese von Stereoisomeren des Muscarins". Experientia 13 (4): 138.  
  11. ^ Cox, H. C.; Hardegger, E.; Kögl, F.; Liechti, P.; Lohse, F.; Salemink, C. A. (1958). "Über Muscarin. 9. Mitteilung. Über die Synthese von racemischem Muscarin, seine Spaltung in die Antipoden und die Herstellung von (−)-Muscarin aus D-Glucosamin". Helvetica Chimica Acta 41: 229.  
  12. ^ Matsumoto, T.; Ichihara, A.; Ito, N. (1969). "A simple, stereospecific synthesis of dl-muscarine and dl-allomuscarine". Tetrahedron 25 (24): 5889.  
  13. ^ Still, W. C.; Schneider, J. A. (1980). "Chelation-controlled synthesis of (.+-.)-muscarine". The Journal of Organic Chemistry 45 (16): 3375.  
  14. ^ Whiting, J.; Au-Young, Y. -K.; Belleau, B. (1972). "A Convenient Synthesis ofL(+)-Muscarine". Canadian Journal of Chemistry 50 (20): 3322.  
  15. ^ Mubarak, A. M.; Brown, D. M. (1980). "A simple, stereospecific synthesis of (+)-muscarine". Tetrahedron Letters 21 (25): 2453.  
  16. ^ Mubarak, A. M.; Brown, D. M. (1982). "A stereospecific synthesis of (+)-muscarine". Journal of the Chemical Society, Perkin Transactions 1: 809.  
  17. ^ Pochet, S.; Huynh Dinh Tam (1982). "Stereospecific synthesis of muscarines and allomuscarines in D- and L-series". The Journal of Organic Chemistry 47 (2): 193.  
  18. ^ Theodore M. Brody, Joseph Larner, Kenneth P. Minneman, ed. (1998). "Chapter 9". Human Pharmacology: Molecular to Clinical (3rd ed.). St. Louis, Mo.: Mosby.  
  19. ^ Roberts Bartholow, “A practical treatise on materia medica and therapeutics”, 1908, ISBN 978-1-143-46767-7,
  20. ^ Fraser, PJ (March 1957). "Pharmacological actions of pure muscarine chloride". Br J Pharmacol Chemother. 12 (1): 47–52.  
  21. ^ Peter G. Waser; Chemistry and pharmacology of muscarine, muscarone and some related compounds; Pharmacology Department, University of Zurich, Switzerland 1961

External links

  • Treatment of muscarine poisoning
  • on ErowidAmanitasPsychoactive
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.